Canada markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.01-0.36 (-1.61%)
At close: 04:00PM EDT
22.01 0.00 (0.00%)
After hours: 04:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close22.37
Bid17.00 x 1400
Ask22.05 x 1100
Day's Range21.90 - 22.58
52 Week Range18.98 - 36.95
Avg. Volume563,350
Market Cap1.768B
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateAug 01, 2022 - Aug 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.33
  • Zacks

    Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down

    Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.

  • Zacks

    Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates

    Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

    Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectivelyEnded the quarter with $339.2 million in cash, cash equivalents and investmentsNew partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selectio